We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Infectious Diseases Diagnosed At Point-of-Care

By LabMedica International staff writers
Posted on 14 Apr 2015
A new “lab-on-a-disc” technology can diagnose malaria and other febrile infectious diseases simultaneously in just an hour, allowing faster point-of-care treatment and precise drugs administration that could save thousands of lives. More...


A major problem with current testing for infectious diseases in Africa is that it focuses on individual diseases and cannot reliably discriminate between them. Since most infectious diseases have the same feverish symptoms, diagnosis is often inaccurate, resulting in thousands of deaths and increased resistance to antimicrobial drugs.

A team of scientists at Freiburg University (Germany) have developed a new diagnostic tool: an easily-portable lab-on-a-disc, which can test for several tropical diseases at the same time, discriminate between them and guide healthcare personnel to proper patient treatment. A health professional injects the patient's blood sample onto a plastic disc, the “LabDisk,” which is roughly the size of a compact disc (CD), and then places the disc in the 'disc player'. The device weighs just 2 kg, making it perfect for transportation to remote villages. The disc has pre-stored biochemical components, which allow fully automated analysis.

The blood sample is processed on disc and centrifugally distributed into microfluidic chambers where the disease pathogens can be identified from their DNA/RNA, whether it be from parasites like malaria, bacteria such as typhoid or pneumonia or for example dengue viruses. This generic point-of-care platform can be applied to many other infectious diseases for example Ebola, only by changing its bio-components. Early diagnosis can help limit the effects of an extended epidemic.

Konstantinos Mitsakakis, PhD, who led the team that developed the platform, said, “It is a very simple and cheap system that can be used in regions with low medical infrastructure. Results can be obtained from a finger prick of blood in just one hour, whereas laboratory culture currently takes up to three days. This could mean very important progress, not just for patient management, but also for epidemiological mapping of regions and countries, as we will be able to monitor the frequency and distribution of various infectious diseases.”

Related Links:

Freiburg University 



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Aspiration System
VACUSAFE
New
HPV Test
Allplex HPV28 Detection
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.